Gemini Therapeutics, Inc. (GMTX) Income Statement Analysis

See more : Mullen Group Ltd. (MLLGF) Income Statement Analysis – Financial Results

Complete financial analysis of Gemini Therapeutics, Inc. (GMTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gemini Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Wakamoto Pharmaceutical Co.,Ltd. (4512.T) Income Statement Analysis – Financial Results
International Paper Company PFD $4 (INPAP) Income Statement Analysis – Financial Results
Sustainable Opportunities Acquisition Corp. (SOAC) Income Statement Analysis – Financial Results
HEXPOL AB (publ) (HXXPY) Income Statement Analysis – Financial Results
Colgate-Palmolive Company (CL) Income Statement Analysis – Financial Results

Gemini Therapeutics, Inc. (GMTX)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.geminitherapeutics.com

About Gemini Therapeutics, Inc.

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Unable to fetch income statement for: GMTX

Is the Options Market Predicting a Spike in Gemini Therapeutics (GMTX) Stock?

August 30, 2021zacks.com

Investors need to pay close attention to Gemini Therapeutics (GMTX) stock based on the movements in the options market lately.

Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

June 22, 2021businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced initial data from its Phase 2a ReGAtta study of GEM103 as of May 2021 in patients...

3 Biotech Stocks With Big Catalysts in June

June 22, 2021fool.com

Important events on the horizon could push these biotech stocks higher or press them further into the dirt.

Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 13, 2021businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today reported its financial results for the first quarter ended March 31, 2021 and provided a business update....

Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 1, 2021businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the presentation of preclinical data at the 2021 Association for Research...

Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

March 29, 2021businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today reported its financial results for the year ended December 31, 2020 and provided a business update....

Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

February 19, 2021businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled...